A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B
NCT03787758
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Huntington Disease
Interventions
DRUG:
SAGE-718
Sponsor
Supernus Pharmaceuticals, Inc.